ESPAC-4: Adjuvant Gemcitabine/Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma

June 3-7, 2016; Chicago, Illinois
Survival benefit was consistent across prognostic criteria of grade, disease stage, lymph node involvement, and resection margins, and there was no significant difference in treatment-related serious adverse events between the 2 treatment arms.
Format: Microsoft PowerPoint (.ppt)
File Size: 678 KB
Released: June 14, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Expert review of key data in GI cancers from the 2022 ASCO Annual Meeting, from Clinical Care Options (CCO)

Christopher H. Lieu, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 31, 2022 Expired: August 30, 2023

Data from the CONKO-007 trial of chemoradiotherapy vs chemotherapy for locally advanced pancreatic cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Michael J. Pishvaian, MD, PhD Released: June 3, 2022

Experts highlight key studies being presented at the 2022 ASCO Annual Meeting in this commentary from Clinical Care Options (CCO)

Allison Betof Warner, MD, PhD John M. Burke, MD Shaji K. Kumar, MD Christopher H. Lieu, MD Stephen V. Liu, MD Joyce O'Shaughnessy, MD Zofia Piotrowska, MD, MHS Angeles Alvarez Secord, MD, MHSc Rachna Shroff, MD Hussein Tawbi, MD, PhD Eunice S. Wang, MD Released: June 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings